68
Views
5
CrossRef citations to date
0
Altmetric
Letter to the Editor

Inhibition of chronic graft-vs-host disease with retention of anti-myeloma effects by the proteasome inhibitor bortezomib

, MD, PhD, , , , , & show all
Pages 1015-1018 | Received 22 Nov 2006, Accepted 27 Jan 2007, Published online: 01 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Federica Cocito, Silvia Mangiacavalli, Paolo Bernasconi, Anna A. Colombo, Daniela Caldera, Claudio S. Cartia, Maya Ganzetti, Daniela Troletti, Mario Cazzola & Alessandro Corso. (2017) Long-term control of extensive refractory chronic graft versus host disease in a multiple myeloma relapsing after allogeneic transplant. A case report. Leukemia & Lymphoma 58:11, pages 2770-2771.
Read now
S. Zweegman, J. J. W. M. Janssen & H. M. Lokhorst. (2007) Immune-modulatory effects of bortezomib in GVHD. Leukemia & Lymphoma 48:5, pages 853-854.
Read now

Articles from other publishers (3)

LaQuisa Hill, Amin Alousi, Partow Kebriaei, Rohtesh Mehta, Katayoun Rezvani & Elizabeth Shpall. (2017) New and emerging therapies for acute and chronic graft versus host disease . Therapeutic Advances in Hematology 9:1, pages 21-46.
Crossref
Alex F. Herrera, Haesook T. Kim, Bhavjot Bindra, Kyle T. Jones, Edwin P. AlyeaIIIIII, Philippe Armand, Corey S. Cutler, Vincent T. Ho, Sarah Nikiforow, Bruce R. Blazar, Jerome Ritz, Joseph H. Antin, Robert J. Soiffer & John Koreth. (2014) A Phase II Study of Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation 20:11, pages 1737-1743.
Crossref
John Koreth, Edwin P. Alyea, William J. Murphy & Lisbeth A. Welniak. (2009) Proteasome Inhibition and Allogeneic Hematopoietic Stem Cell Transplantation: A Review. Biology of Blood and Marrow Transplantation 15:12, pages 1502-1512.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.